Raymond James Has Negative Forecast for TSE:MDP Q3 Earnings

Medexus Pharmaceuticals Inc. (TSE:MDPFree Report) – Investment analysts at Raymond James dropped their Q3 2026 EPS estimates for shares of Medexus Pharmaceuticals in a report released on Tuesday, January 7th. Raymond James analyst M. Freeman now forecasts that the company will post earnings per share of $0.22 for the quarter, down from their previous estimate of $0.24. Raymond James has a “Strong-Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q4 2026 earnings at $0.23 EPS, FY2026 earnings at $0.89 EPS, FY2027 earnings at $0.88 EPS, FY2028 earnings at $0.80 EPS and FY2029 earnings at $0.77 EPS.

A number of other research analysts have also commented on the company. Leede Financial set a C$8.25 price objective on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research report on Monday, September 30th. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Two research analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Strong Buy” and a consensus target price of C$5.25.

Read Our Latest Report on MDP

Medexus Pharmaceuticals Price Performance

Shares of Medexus Pharmaceuticals stock opened at C$4.04 on Thursday. The firm has a 50 day simple moving average of C$2.77 and a 200 day simple moving average of C$2.53. Medexus Pharmaceuticals has a fifty-two week low of C$1.47 and a fifty-two week high of C$4.24. The firm has a market cap of C$99.10 million, a P/E ratio of 80.80 and a beta of 1.96.

About Medexus Pharmaceuticals

(Get Free Report)

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

Further Reading

Earnings History and Estimates for Medexus Pharmaceuticals (TSE:MDP)

Receive News & Ratings for Medexus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medexus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.